Talazoparib is under clinical development by Pfizer and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Talazoparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Talazoparib overview

Talazoparib (Talzenna, Tarzena) is an anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. It is indicated for the treatment of adult patients with deleterious, suspected deleterious germline breast cancer susceptibility gene (BRCA) -mutated ( gBRCAm ) human epidermal growth factor receptor 2 (HER2)- negative locally advanced or metastatic breast cancer with a mutation in homologous-recombination deficient (HRD) pathway genes, and as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC), recurrent breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor-positive (HR+) breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.

Talazoparib (BMN-673) is under development for the treatment of malignant pleural mesothelioma, advanced or metastatic solid tumor, myelodysplastic syndrome, genetically defined cancers including gastric cancer, triple-negative breast cancer, pancreatic cancer, metastatic castration-resistant prostate cancer, small-cell lung cancer, metastatic non-squamous non-small cell lung cancer, acute myeloid leukemia (AML), HER2 negative breast cancer, epithelial ovarian cancer, relapsed or refractory Ewing's sarcoma, cervical cancer, hormone-sensitive prostate cancer, colorectal cancer, gastroesophageal junction adenocarcinoma, metastatic urothelial carcinoma, renal pelvis cancer, upper urinary tract cancer and bladder cancer, urethral cancer. The drug candidate is administered orally, and it is a new molecular entity (NME). BMN-673 is a Poly ADP-ribose polymerase (PARP) inhibitor. It was also under development for pancreatic ductal adenocarcinoma, myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), colorectal cancer, epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer and glioblastoma multiforme.

It was also under development for gastric cancer, peritoneal cancer, ovarian cancer and metastatic breast cancer.

Pfizer overview

Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of Talazoparib’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.